← Eichor
Study identifier: NCT06088212 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor

Condition: Heart Failure · Cognitive Impairment · Dementia  ·  Sponsor: Baker Heart and Diabetes Institute

PhaseNA
Planned participants168
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. Findings from this research will transform the way healthcare is delivered to cognitively impaired patients with heart disease who have a very high risk of developing dementia.

This description comes directly from the study's public registry record.

Talk to the study team

Quan Huynh  ·  610385321833  ·  quan.huynh@baker.edu.au

Always discuss trial participation with your own doctor first.

Locations (1)

Menzies Institute for Medical ResearchHobart, Tasmania, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06088212